VEGFA genomic amplification tailors treatment of HCCs with Sorafenib

Cancer Discovery

Volumn 4, Issue 6, 2014, Pages 640-641

  Luo, Xiaolin ^a   Feng, Gen Sheng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAF PROTEIN; SCATTER FACTOR; SORAFENIB; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COMPARATIVE GENOMIC HYBRIDIZATION; DNA SEQUENCE; DRUG COST; GENE AMPLIFICATION; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; MACROPHAGE; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; FEMALE; LIVER NEOPLASMS; MALE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904055643     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0406     Document Type: Article

References (10)

1. Stewart BW, Wild CP, editors. World cancer report 2014: Lyon, France: IARC; 2014.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
6. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-300.
7. Horwitz E, Stein I, Andreozzi M, Nemeth J, Shoham A, Pappo O, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov 2014;4: 730-43.
8. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299: 890-3.
9. Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52 (Suppl 3): iii1-8.
10. Feng GS. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 2012; 21: 150-4.